

Claris Lifesciences Limited

Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
 website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com , CIN : L85110GJ1994PLC022543

Unaudited Financial Results for the Quarter and Half Year ended June 30, 2014

(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated						Standalone					
	Quarter Ended			Year to Date		Year ended	Quarter Ended			Year to Date		Year ended
	30th June 2014	31st Mar 2014	30th June 2013	30th June 2014	30th June 2013	31st Dec 2013	30th June 2014	31st Mar 2014	30th June 2013	30th June 2014	30th June 2013	31st Dec 2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART II												
A PARTICULARS OF SHAREHOLDING												
1. Public Shareholding												
- No. of shares	21,285,801	25,392,554	25,392,554	21,285,801	25,392,554	25,392,554	21,285,801	25,392,554	25,392,554	21,285,801	25,392,554	25,392,554
- Percentage of shareholding	39.01	39.79	39.79	39.01	39.79	39.79	39.01	39.79	39.79	39.01	39.79	39.79
2. Promoters and Promoter group shareholding												
a) Pledged/Encumbered												
- Number of shares	5,928,384	6,844,532	6,834,000	5,928,384	6,834,000	-	5,928,384	6,844,532	6,834,000	5,928,384	6,834,000	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.81	17.81	17.79	17.81	17.79	-	17.81	17.81	17.79	17.81	17.79	-
- Percentage of shares (as a % of the total share capital of the Company)	10.86	10.73	10.71	10.86	10.71	-	10.86	10.73	10.71	10.86	10.71	-
b) Non-encumbered												
- Number of Shares	27,353,580	31,580,679	31,591,211	27,353,580	31,591,211	38,425,211	27,353,580	31,580,679	31,591,211	27,353,580	31,591,211	38,425,211
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.19	82.19	82.21	82.19	82.21	100.00	82.19	82.19	82.21	82.19	82.21	100.00
- Percentage of shares (as a % of the total share capital of the Company)	50.13	49.49	49.50	50.13	49.50	60.21	50.13	49.49	49.50	50.13	49.50	60.21
B INVESTOR COMPLAINTS												
Pending at the beginning of the quarter							Nil					
Received during the quarter							14					
Disposed of during the quarter							13					
Remaining unresolved at the end of the quarter							1					

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th August, 2014
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 During the quarter under review, the company has bought-back 92,50,000 number of equity shares of the company of Rs 10/-each fully paid up at the rate of Rs 250/- per equity share after complying with the provisions of the Companies Act / Rules framed thereunder in this regard through "Tender Offer" route as prescribed under the Securities and Exchange Board of India (Buy- back of Securities) Regulations, 1998. On account of above buy-back, the paid up share capital of the company is reduced by Rs 925.00 lacs and securities premium is reduced by Rs 22,200.00 lacs.
- 4 Consequent to the applicability of the Companies Act, 2013 with effect from 1st April 2014, during the quarter ended 30th June 2014, the management has reassessed the remaining useful life of assets based on internal and external technical evaluations and accordingly depreciation provision has been made for the quarter ended 30th June 2014.
- 5 On July 4, 2014, the Board of Directors of the Company has approved the transfer of the Speciality Injectable business of the Company by way of slump sale as a "going concern" to its wholly-owned subsidiary Company. The transfer of the business is subject to the approval of shareholders' and other approvals as may be applicable.
- 6 Statement of Assets and Liabilities

(Rs. In Lacs)

Particulars	Consolidated		Standalone	
	As at 30th June 2014	As at 31st Dec 2013	As at 30th June 2014	As at 31st Dec 2013
	Unaudited	Audited	Unaudited	Audited
A. EQUITY AND LIABILITIES				
1. Shareholders' Funds:				
Share Capital	5,456.78	6,381.78	5,456.78	6,381.78
Reserves and Surplus	113,983.11	134,047.69	69,448.53	88,631.40
Sub-total - Shareholders' funds	119,439.89	140,429.47	74,905.31	95,013.18
2. Minority Interest	-	-	-	-
3. Non - current liabilities				
Long-term borrowings	31,334.71	12,682.94	31,334.71	12,682.94
Deferred tax liabilities (net)	5,963.86	5,878.19	5,983.04	5,896.85
Other long-term liabilities	-	-	-	-
Long-term provisions	677.68	641.50	626.98	591.12
Sub-total - Non-current liabilities	37,976.25	19,202.63	37,944.73	19,170.91
4. Current liabilities				
Short-term borrowings	11,215.92	10,546.65	11,215.92	10,546.65
Trade payables	10,343.90	10,828.80	9,658.53	10,317.21
Other current liabilities	21,742.79	21,044.98	28,792.92	29,282.17
Short-term provisions	474.29	9,039.21	460.54	9,009.93
Sub-total - Current liabilities	43,776.90	51,459.64	50,127.91	59,155.96
TOTAL - EQUITY AND LIABILITIES	201,193.04	211,091.74	162,977.95	173,340.05
B. ASSETS				
1. Non - current assets				
Goodwill on Consolidation	3.20	3.20	-	-
Fixed assets	91,187.81	74,483.14	75,601.88	67,841.99
Non - current investments	20,684.29	20,950.07	1,860.62	1,860.62
Long-term loans and advances	12,138.82	19,467.12	11,859.18	9,510.19
Other non-current assets	-	-	-	-
Sub-total - Non-current assets	124,014.12	114,903.53	89,321.68	79,212.80
2. Current assets				
Current investments	32,779.09	60,881.99	32,779.09	60,881.99
Inventories	5,074.39	4,497.42	4,525.72	3,925.32
Trade receivables	14,791.43	15,651.27	13,276.11	15,479.09
Cash and cash equivalents	17,090.80	9,459.35	16,243.03	8,912.85
Short -term loans and advances	5,559.64	4,534.88	4,948.75	3,764.70
Other current assets	1,883.57	1,163.30	1,883.57	1,163.30
Sub-total - Current assets	77,178.92	96,188.21	73,656.27	94,127.25
TOTAL - ASSETS	201,193.04	211,091.74	162,977.95	173,340.05

7 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Limited

Place : Ahmedabad
Date 11th August , 2014

Arjun Handa
Managing Director & CEO